Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

INTRODUCTION: EGFR mutations drive a subset of NSCLC. Patients harboring the common EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect of osimertinib on NSCLC with atypical EGFR mutations is not well desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Jingran, Aredo, Jacqueline V., Piper-Vallillo, Andrew, Huppert, Laura, Rotow, Julia K., Husain, Hatim, Stewart, Susan, Cobb, Rosemary, Wakelee, Heather A., Blakely, Collin M., Wong, Melisa L., Gubens, Matthew A., Madani, Mohammad H., Digumarthy, Subba R., McCoach, Caroline, Piotrowska, Zofia, Neal, Joel W., Riess, Jonathan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984841/
https://www.ncbi.nlm.nih.gov/pubmed/36879929
http://dx.doi.org/10.1016/j.jtocrr.2022.100459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984841/
https://www.ncbi.nlm.nih.gov/pubmed/36879929
http://dx.doi.org/10.1016/j.jtocrr.2022.100459

Ejemplares similares